WSLHD
Skip navigation
Please use this identifier to cite or link to this item: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/2553
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMahony, M.-
dc.contributor.authorMcMullan, B.-
dc.contributor.authorBrown, Jeremy D.-
dc.contributor.authorKennedy, S. E.-
dc.date.accessioned2021-09-29T07:13:29Z-
dc.date.available2021-09-29T07:13:29Z-
dc.date.issued2020-
dc.identifier.citationPediatric Nephrology. 35(9):1563-1573, 2020 Sep-
dc.identifier.urihttps://wslhd.intersearch.com.au/wslhdjspui/handle/1/2553-
dc.description.abstractThe global spread of multidrug-resistant organisms has led to an increase in urinary tract infections (UTIs) in children that are difficult to treat. This review explores the current literature regarding multidrug-resistant UTIs in childhood and proposes an approach to management. Multidrug-resistant organisms include a wide range of potential urinary tract pathogens and, while most literature on drug resistance in UTIs during childhood has focused on extended-spectrum beta-lactamase producing organisms, in this review, we have included a discussion of multidrug resistance including and beyond beta-lactamase production. We provide definitions for multidrug-resistant organisms in line with current consensus guidelines and summarise clinically relevant mechanisms of resistance. Additionally, in this review, we outline the global epidemiology of multidrug-resistant UTIs in children, summarising published prevalence rates, which range from 5 to 90% in different settings. Finally, we also critically review the evidence on risk factors for colonisation and infection of the urinary tract with multidrug-resistant organisms, including prior antibiotic use, hospitalisation and underlying urological malformations. We also highlight multidrug-resistant UTI occurring in children without any identifiable risk factors, reflecting an increasing prevalence of colonisation with these organisms in the general community. Taken as a whole, this emphasises a need for careful and evidence-based use of antibiotics when treating UTIs in children and, to aide clinicians, we have outlined here potential management strategies for when infection with a multidrug-resistant organism is suspected or confirmed. Copyright © 2019, IPNA.-
dc.subjectInfectious Diseases-
dc.titleMultidrug-resistant organisms in urinary tract infections in children-
dc.typeJournal article-
dc.identifier.doihttp://dx.doi.org/10.1007/s00467-019-04316-5-
dc.subject.keywordsChildren-
dc.subject.keywordsExtended-spectrum beta-lactamases-
dc.subject.keywordsMultidrug resistance-
dc.subject.keywordsUrinary tract infection-
dc.subject.keywordsconsensus-
dc.subject.keywordshospitalization-
dc.subject.keywordsrisk factor-
dc.subject.keywordsurinary tract malformation-
dc.subject.keywordsantibiotic agent-
dc.subject.keywordsextended spectrum beta lactamase-
dc.identifier.journaltitlePediatric Nephrology-
dc.identifier.departmentInfectious Diseases-
dc.identifier.pmid2002547326-
dc.identifier.pmid31418063-
dc.contributor.wslhdBrown, Jeremy D.-
dc.identifier.facilityBlacktown-
dc.identifier.facilityMount Druitt-
dc.type.studyortrialReview-
dc.type.studyortrialPractice Guideline-
Appears in Collections:WSLHD publications

Files in This Item:
File Description SizeFormat  
Mahony-2020-Multidrug-resistant organisms in u.pdf521.78 kBAdobe PDFThumbnail
View/Open


Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.